5-Alpha Reductase Inhibitors and Risk of Kidney and Bladder Cancers in Men with Benign Prostatic Hyperplasia: A Population-Based Cohort Study.
Niamh DohertyChristopher R CardwellPeter MurchieChristopher HillLaurent AzoulayBlánaid M HicksPublished in: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology (2023)
The findings of this study indicate that 5-alpha reductase inhibitors are unlikely to reduce kidney or bladder cancer risk.